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Abstract. Background: Hepatitis C virus (HCV)
remains very prevalent in injection drug users
(IDUs). In spite of recommended vaccinations
against hepatitis A virus (HAV) and hepatitis B virus
(HBV), many IDUs remain susceptible to HAV and
HBV. Study population and methods: Patients enter-
ing heroin-assisted treatment between 2000 and 2002
(N = 210) were compared for infectious disease
status with patients entering this treatment in 1998
(N = 243) and between 1994 and 1996 (N = 1035).
Infection status was determined with the aid of
questionnaires and blood tests for antibodies against
HAV, HBV core antigen, HCV and HIV. Results: In
the cohort 2000–2002 78.3% of the patients were
HCV positive, 53.3% were HBV positive, 41.2% were
HAV positive and 12.6% were HIV positive. In
comparison to the cohorts entering the heroin-
assisted treatment at an earlier time, there was a
signiﬁcant reduction of HBV and HAV infections,
but not of HCV and HIV infections. 15.6% of the
patients entering between 2000 and 2002 were vacci-
nated against HBV and 10.3% against HAV. 31.1%
of patients at entrance were susceptible for HBV and
48.5% for HAV. In comparison to patients entering
treatment in 1998 there was no signiﬁcant increase in
patients who were vaccinated against HBV.
Conclusions: This data illustrates the need for
improving HCV prevention and more consequent
vaccination against HBV and HAV in IDUs.
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Abbreviations anti-HAV = antibodies against HAV; anti-HBc = antibodies against HBV core antigen; anti-
HBs = antibodies against HBV surface antigen; anti-HCV = antibodies against HCV; anti-HIV = antibodies
against HIV; HAT = heroin- assisted treatment; HAV = hepatitis A virus; HBV = hepatitis B virus; HCV =
hepatitis C virus; HIV = human immunodeﬁciency virus; IDU = injection drug user
Introduction
Injection drug use carries a high risk of aquiring
parenterally transmitted viruses like HBV, HCV and
HIV. HCV is transmitted especially frequently
through injection drug use due to its high rate of
chronicity, high prevalence among IDUs and rela-
tively high viremia. After the introduction of anti-
HCV screening of blood donors, injection drug use is
the main transmission route of HCV in countries like
USA, Australia, Germany and Switzerland [1–4]. In
Western Europe, the prevalence of HCV in IDU
populations is between 40 and almost 100% [5–14].
The prevalence of HBV infections among IDU pop-
ulations in Western European countries is between 20
and 70% [7–14]. For HAV infections among IDUs,
studies from Switzerland, Germany, Canada and
USA report a prevalence of about 30% and higher
[10, 15–17]. Only a fraction of IDUs who are sus-
ceptible to HBV are vaccinated against this virus [11,
18–20]. In Switzerland the combined HAV/HBV
vaccination is recommended for IDUs [21, 22]. The
prevalence of HIV infections among IDUs in coun-
tries of the European Union is in general stable or
decreasing [23]. In Switzerland, Germany, Great
Britain and Sweden, regional or national studies of
the middle and late 1990s in diﬀerent settings show
HIV prevalences in IDUs between 1 and 15% [7–14].
Heroin-assisted treatment (HAT) started in Swit-
zerland in 1994. After a pilot phase, which ended
in 1996, the treatment programme was continued
and is now part of the regular treatment system in
Switzerland. The treatment is provided by special
treatment centers. Currently, there are 23 of these
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centers in the German and French speaking parts of
Switzerland. Criteria for admission to the HAT are a
heroin addiction (ICD-10 deﬁnition) of at least
2 years, an age of at least 18 years, at least two pre-
vious treatment attempts and physical, psychological
or social deﬁciencies. When there are major deﬁ-
ciencies of these types, an admission without previous
treatment attempts is possible. Due to the continuous
monitoring system of HAT (data at the entry, during
and at the end of the treatment) it is possible to
monitor the prevalence of hepatitis virus and HIV
infections in a group of IDUs and thereby get indi-
cators of possible eﬀectiveness of preventive measures
for reducing these viruses in IDUs.
Study population and method
The sample consisted of IDUs who entered the HAT
for the ﬁrst time between November 2000 and June
2002. 104 readmissions and 69 patients who changed
the treatment center during this time period where
not included in the sample. Incomplete data (none or
only one of two obligatory questionnaires) was an-
other exclusion criteria. This was the case for 166 out
of the 376 newly admitted patients. Missing entrance
forms are mainly due to individual work load of staﬀ
in the treatment centers and apparently does not
correlate with patient characteristics. Using t-test,
respectively v2-test, age and sex of the 166 patients
with missing entrance forms did not diﬀer signiﬁ-
cantly to the 210 patients with complete entrance
forms. The results of this sample (N = 210) were
compared with previous results on persons who en-
tered this treatment in 1998 (N = 243) and between
1994 and 1996 (N = 1035). The questionnaires were
routinely answered at the beginning of the treatment,
completed by the staﬀ of the treatment centers and
sent in anonymous form to the Research Institute for
Public Health and Addiction in Zurich. Serum sam-
ples were tested at entry in 54% (HCV), 56% (HBV,
HIV) and 61% (HAV) of the test results, depending
on the data already available. Treatment centers do
not test patients at entry if they were tested within
6 months before entering the HAT, and no exposure,
e.g. sharing of needles, was identiﬁed within this time
period. The following infection markers were as-
sayed: anti-HAV for a HAV (if vaccination was not
reported), anti-HBc for HBV; anti-HCV and/or a
positive HCV-PCR test for HCV and anti-HIV for
HIV. The presence of anti-HBs without anti-HBc was
considered as a marker for a previous successful
vaccination against HBV. In virtually all patients
(>97%) injection drug consumption could be con-
ﬁrmed for the period before entering HAT. The
prevalence ratios in the three admission cohorts were
statistically compared by v2-tests (with Yates cor-
rection and df = 1), using a level of signiﬁcance of
p<0.05.
Results
The population of the recent study (entrance between
the years 2000 and 2002) consists mostly of men
(82.4%), the average age was 33.7 years (range 21–
50 years) (see Table 1). More than half of the patients
consumed heroin for more than 10 years, the average
time was 11.6 years (range 2–27 years). The median
of onset of injection drug use was at an age of
19 years. All patients were in drug dependence
treatment before admission to the HAT and most of
them were in a methadone maintenance treatment
programme at least once. About half of the patients
participated previously in drug dependence treatment
programmes more than seven times.
Prevalence of hepatitis virus and HIV infections
The results of the current in comparison to previous
studies is shown in Table 1. The prevalence of HCV
was 78.3% (137 of 175 test results). Compared to
patients who entered HAT at an earlier time, there
was no signiﬁcant change.
For HBV, a signiﬁcant decrease was found in the
cohort of 2000–2002 (53.3%, 89 of 167 tested pa-
tients) compared to admissions in 1998 and to
admissions between 1994 and 1996. The prevalence of
anti-HAV without previous vaccination in the cohort
2000–2002 was 41.2% (56 of 136 test results). For the
cohort 1998 no results for HAV were available. In
1994–1996 the prevalence was 70%. This number
may include a small number of vaccinated persons,
but this is most likely not the reason for the highly
signiﬁcant decrease from 1994 to 2002, because vac-
cination against HAV was not often done at that
time.
The prevalence of HIV in admissions between 2000
and 2002 was 12.6% (21 of 167 test results). The
percentage of HIV positive patients has not changed
signiﬁcantly compared to patients who entered
treatment in 1998 and to persons who entered be-
tween 1994 and 1996.
Vaccination against hepatitis A and B
Among the patients entering HAT between 2000 and
2002 only 15.6% (26 of 167 test results) were suc-
cessfully vaccinated against HBV. Thus, the per-
centage of HBV vaccinated patients has not changed
signiﬁcantly since 1998 (v2 = 2.8), when 8% (10 of
121) were vaccinated against HBV at admission. The
percentage of patients who were vaccinated against
HAV was 10.3% (14 of 136). For 1998 and for 1994–
1996 the vaccination status was not recorded.
Fortynine patients of 167 (31.1%) were anti-HBc
and anti-HBs negative and thus susceptible for an
HBV infection. For 36 of these patients (73.5%) an
HBV vaccination was planned during the treatment.
Eleven patients (22.4%) refused to be vaccinated, and
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for 2 persons (4.1%) an unspeciﬁed medical contra-
indication was declared. Concerning HAV, 57 out of
136 patients (48.5%) were susceptible to this infec-
tion. For 34 persons (59.6%), an HAV vaccination
was planned during HAT, 18 persons (31.6%) re-
fused such an vaccination, and for 5 persons (8.8%)
an unspeciﬁed medical contraindication was declared.
Discussion
As conﬁrmed by this study, HCV infection remains
the most prevalent serious virus infection in IDUs,
and no decrease within 8 years could be shown. The
prevalences of HBV and HAV have moderately, but
signiﬁcantly decreased, but were still high at 53.3%,
and 41.2% respectively. HAV [24–27] and HBV
infections are transmitted easily in the viremic phase,
but since HAV never and HBV (in immune compe-
tent adults) only rarely becomes chronic (in about
5–10% of infections), the chance of acquiring the
infection by occasional sharing of injection devices is
not so high as with HCV. The number of HAV
infections could not be determined reliably, however.
Anti-HAV could have been indicative of an unre-
ported vaccination since during diﬀerent medical
procedures and vaccinations, the HAV vaccination
may have not been recognized by the patient. Re-
cently notiﬁcation of IDU related HAV infections to
the Public Health Oﬃce of Switzerland is requested
to achieve a better appraisal of the epidemiological
situation [28]. Besides insuﬃcient injection hygiene,
the life style of IDUs and contamination of the drugs
may be a reason for the high prevalence of HAV and
HBV. The decrease in HAV and HBV infections is
presumably linked to less sharing of injection devices
and more hygienic environments of IDUs in the last
10 years.
The HIV prevalence of 12–15% in this study is
30–38 times higher than in the general Swiss adult
population [29] and no signiﬁcant decrease was ob-
served. IDUs on methadone maintenance treatment
in Switzerland had 6.4% prevalence [9] and 5% of the
patients who entered an abstinence orientated ther-
apy in Switzerland in 2004, reported a positive HIV
test [30]. In England and Wales, a HIV prevalence in
IDUs of only 0.9% was found at the end of the 1990s
[31].
The majority of patients was still susceptible to
HBV or HAV although in Switzerland the combined
Table 1. Prevalence of hepatitis virus and HIV infections
(1) Admissions
2000–2002
(N = 210)
This study
(2) Admissions
1998 (N = 243)
Bla¨ttler et al. (2000)
(3) Admissions
1994–1996 (N = 1035)
Steﬀen et al. (2001)
v2-tests:
A (1) versus (2)
B (1) versus (3)
Sex
Female 17.6% (37) 35% (136) 30% (310)
Male 82.4% (173) 65% (249) 70% (725)
Age
Average age 33.7 32 30.8
Hepatitis C virus
Positive 78.3% (137) 76% (137) 82% (706) A v2 = 0.1 n.s.
B v2 = 1.2 n.s.
Missing values 35 63 176
Hepatitis B virus
Positive 53.3% (89) 68% (112) 73.2% (625) A v2 = 7.2
p<0.01
B v2 = 25.3
p<0.001
Missing values 43 79 181
Hepatitis A virus Not available
Positive 41.2% (56) 70% (592) B v2 = 27.1
p<0.001
Positive, vaccinated 10.3% (14) Not available
Missing values 74 190
HIV
Positive 12.6% (21) 14% (33) 15.3% (138) A v2 = 0.09 n.s.
B v2 = 0.07 n.s.
Missing values 43 10 136
n.s. = not signiﬁcant.
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HAV/HBV vaccination of IDUs is recommended.
This is particularly disappointing because all of the
patients were in drug treatment at least once before
HAT and most even several times. The mean age of
IDUs studied increased over time, probably indicat-
ing that IDUs in Switzerland are an aging popula-
tion. In this the case, the number of susceptibles for
HAV- and HBV infections will decrease indepen-
dently of vaccination. Nevertheless, it needs to be
discussed why the recommendation to vaccinate
IDUs is not implemented widely and how higher
vaccination rates could be achieved.
Even more concern is raised by the unaltered high
prevalence of HCV. It is essential that newly-starting
IDUs are reached as early as possible, because shar-
ing of syringes seems to be common in the beginning
of injection drug use [19, 32]. Syringe or needle
sharing is especially risky with older IDUs, since
these persons are very often infected [6, 33, 34].
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